Panel To Review Labeling Change For Digene's Hybrid Capture CMV Test
This article was originally published in The Gray Sheet
Whether Digene's Hybrid Capture cytomegalovirus DNA test technology truly incorporates signal amplification will be discussed at a May 20 meeting of FDA's Microbiology Devices Advisory Panel. Digene seeks to include this claim in its labeling for two reasons, according to the Beltsville, Maryland-based firm: higher reimbursement and competitive positioning.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.